Oct 10, 2019
MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)
Jan 24, 2019
MGB Biopharma - FDA and Health Canada Clear IND/CTA Applications for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)
Oct 23, 2018
GenePOC® Launches its GenePOC® CDiff Test in Canada
Oct 15, 2018
St. Vincent Healthcare Implements Facility-Wide Strategy to Combat Infections
Oct 15, 2018
Fairfield Medical Center Achieves a Major Patient Safety Milestone
Oct 04, 2018
Acurx Pharmaceuticals to Enter Clinical Trials with First-In-Class Antibiotics to Treat Selected Gram-Positive Bacterial Infections
Oct 01, 2018
Ecolab Obtains First-to-Market EPA-Registered Laundry Disinfectant Claim against Clostridium difficile
Aug 14, 2018
UV Light Challenged by Altapure
Aug 14, 2018
The Microbiome Therapeutics Innovation Group Announces Coalition Formation and Leadership Team
Jun 20, 2018
FDA Grants QIDP Designation to Acurx's Lead Antibiotic Product Candidate, ACX-362E for Clostridium Difficile Infection
Jun 08, 2018
Microbiome Health Index(TM) Platform, Outcomes of Rebiotix's RBX7455 Oral Formulation To Be Featured in Rapid Fire and Poster Sessions at ASM Microbe 2018
Jun 04, 2018
Rebiotix Microbiota Restoration Therapy(TM) Products, Microbiome Health Index(TM) to Take Center Stage at Digestive Disease Week 2018
Apr 23, 2018
Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection
Mar 27, 2018
Hemet Valley Medical Center Implements Cutting-edge UV Technology to Enhance Patient Safety and Help Eradicate Healthcare-Associated Infections
Feb 26, 2018
TECHLAB® Products Identified As Meeting Updated Clinical Practice Guidelines For Clostridium Difficile Infection
Feb 20, 2018
New IDSA/SHEA Guidelines Highlight Critical Role of PCR Testing in C. difficile Diagnosis
Feb 12, 2018
Rebiotix Develops Microbiome Health Index(TM) to Identify Indicators for Microbiome Restoration
Feb 05, 2018
Worldwide Clostridium Difficile Infection Treatment Market to Reach US$ 1,316.7 Mn by 2025 - Persistence Market Research
Jan 29, 2018
CutisPharma Announces FDA Approval Of FIRVANQ(TM) For Treatment Of Clostridium Difficile Associated Diarrhea (CDAD) And Staphylococcus Aureus Colitis
Jan 09, 2018
Rebiotix Highlights 2017 Achievements and 2018 Objectives